Innate Pharma in-licenses OREGA biotech's first-in-class anti-CD39 checkpoint inhibitor program
This program, currently in preclinical development, aims at developing an anti-CD39 mAb; Targeting the adenosine immunosuppressive pathway has potential to promote anti-tumor immune responses across a wide range of tumors; Anti-CD39 broadens Innate Pharma…